Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the...

por Branchoux, S., Sofeu, C.L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C., Rondeau, V.
Publicado 2021

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)

por Tarhini, A.A., Toor, K., Chan, K., McDermott, D.F., Mohr, P., Larkin, J., Hodi, F.S., Lee, C.-H., Rizzo, J.I., Johnson, H., Moshyk, A., Rao, S., Kotapati, S., Atkins, M.B.
Publicado 2021